Pro Share Advisors LLC Revance Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

  • $42.5 Billion
  • Q4 2024

A detailed history of Pro Share Advisors LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 75,252 shares of RVNC stock, worth $193,397. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,252
Previous 63,097 19.26%
Holding current value
$193,397
Previous $162,000 19.14%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
BUY
N/A
12,155 Added 19.26%
75,252 $193,000
Q3 2024

Nov 13, 2024
BUY
$2.57 - $2.57 $115,495 - $115,495
44,940 Added 247.51%
63,097 $162,000
Q2 2024

Aug 13, 2024
SELL
$2.34 - $4.73 $8,767 - $17,723
-3,747 Reduced 17.11%
18,157 $46,000
Q1 2024

May 08, 2024
BUY
$4.65 - $9.31 $8,411 - $16,841
1,809 Added 9.0%
21,904 $107,000
Q4 2023

Feb 14, 2024
BUY
$5.81 - $11.2 $20,387 - $39,300
3,509 Added 21.16%
20,095 $176,000
Q3 2023

Nov 13, 2023
BUY
$11.47 - $25.07 $3,418 - $7,470
298 Added 1.83%
16,586 $190,000
Q2 2023

Aug 10, 2023
BUY
$24.7 - $37.61 $25,811 - $39,302
1,045 Added 6.86%
16,288 $412,000
Q1 2023

May 11, 2023
SELL
$18.36 - $35.27 $35,802 - $68,776
-1,950 Reduced 11.34%
15,243 $490,000
Q4 2022

Feb 02, 2023
BUY
$18.32 - $30.66 $57,451 - $96,149
3,136 Added 22.31%
17,193 $317,000
Q3 2022

Nov 04, 2022
BUY
$14.33 - $28.47 $7,394 - $14,690
516 Added 3.81%
14,057 $379,000
Q2 2022

Aug 01, 2022
SELL
$11.52 - $20.4 $80,812 - $143,106
-7,015 Reduced 34.13%
13,541 $187,000
Q1 2022

May 10, 2022
SELL
$12.36 - $20.31 $60,180 - $98,889
-4,869 Reduced 19.15%
20,556 $400,000
Q4 2021

Feb 08, 2022
BUY
$12.46 - $27.87 $13,519 - $30,238
1,085 Added 4.46%
25,425 $414,000
Q3 2021

Nov 12, 2021
SELL
$25.78 - $33.21 $173,293 - $223,237
-6,722 Reduced 21.64%
24,340 $678,000
Q2 2021

Aug 13, 2021
BUY
$26.8 - $31.84 $117,518 - $139,618
4,385 Added 16.44%
31,062 $921,000
Q1 2021

May 14, 2021
BUY
$24.03 - $29.97 $59,282 - $73,935
2,467 Added 10.19%
26,677 $746,000
Q4 2020

Feb 09, 2021
BUY
$23.41 - $28.34 $137,463 - $166,412
5,872 Added 32.02%
24,210 $686,000
Q3 2020

Nov 13, 2020
BUY
$23.23 - $34.3 $34,937 - $51,587
1,504 Added 8.93%
18,338 $461,000
Q2 2020

Aug 03, 2020
BUY
$12.6 - $26.55 $84,571 - $178,203
6,712 Added 66.31%
16,834 $411,000
Q1 2020

May 15, 2020
SELL
$12.46 - $27.81 $71,657 - $159,935
-5,751 Reduced 36.23%
10,122 $150,000
Q4 2019

Feb 12, 2020
SELL
$11.66 - $20.15 $12,604 - $21,782
-1,081 Reduced 6.38%
15,873 $258,000
Q3 2019

Nov 12, 2019
BUY
$10.22 - $14.5 $602 - $855
59 Added 0.35%
16,954 $220,000
Q2 2019

Aug 13, 2019
SELL
$10.67 - $15.49 $23,676 - $34,372
-2,219 Reduced 11.61%
16,895 $219,000
Q1 2019

May 15, 2019
BUY
$15.4 - $20.39 $48,048 - $63,616
3,120 Added 19.51%
19,114 $301,000
Q4 2018

Feb 14, 2019
SELL
$18.06 - $24.96 $55,697 - $76,976
-3,084 Reduced 16.17%
15,994 $322,000
Q3 2018

Nov 14, 2018
SELL
$23.55 - $30.1 $16,555 - $21,160
-703 Reduced 3.55%
19,078 $474,000
Q2 2018

Aug 13, 2018
SELL
$27.45 - $33.35 $14,438 - $17,542
-526 Reduced 2.59%
19,781 $543,000
Q1 2018

May 14, 2018
BUY
$29.15 - $37.4 $6,937 - $8,901
238 Added 1.19%
20,307 $625,000
Q4 2017

Feb 14, 2018
BUY
$24.55 - $36.3 $28,748 - $42,507
1,171 Added 6.2%
20,069 $717,000
Q3 2017

Nov 13, 2017
BUY
$22.55 - $28.1 $31,051 - $38,693
1,377 Added 7.86%
18,898 $521,000
Q2 2017

Aug 11, 2017
BUY
N/A
17,521
17,521 $463,000

Others Institutions Holding RVNC

# of Institutions
208
Shares Held
80.9M
Call Options Held
2.26M
Put Options Held
5.48M
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email